Actithera Raises $75.5M to Revolutionize Radioligand Therapy
Deal News | Jul 09, 2025 | PR Newswire Cision Actithera
Actithera, a biotech company specialized in radiopharmaceuticals, raised $75.5 million in an oversubscribed Series A financing round. The company aims to redefine precision radioligand therapy, focusing on enabling prolonged tumor retention using its proprietary three-pillar discovery platform. The funds were acquired with involvement from M Ventures, Hadean Ventures, Sofinnova Partners, and 4BIO Capital, among others. Actithera's platform employs covalent targeting strategies to optimize tumor retention and improve safety and efficacy. The company will use the funding to advance its fibroblast activation protein-targeting candidate into clinical development and expand its pipeline. Actithera was founded by Dr. Andreas Goutopoulos, who is noted for his expertise in drug discovery and development. As part of the investment round, new members will join the company’s board to further support its innovation in radioligand therapies aimed at transforming oncology treatment paradigms.
Sectors
- Biotechnology
- Venture Capital
- Healthcare
Geography
- Norway – Oslo, Norway is one of the headquarters of Actithera and also where Hadean Ventures is based.
- United States – Actithera has a significant presence in Cambridge, Massachusetts, USA, contributing to its research and development efforts.
- Europe – Several investors like Sofinnova Partners and M Ventures have their operations based in various European countries.
Industry
- Biotechnology – The article discusses Actithera, a biotech company, focusing on the development of novel radioligand therapies for cancer treatment.
- Venture Capital – The funding round involves several venture capital firms like M Ventures, Hadean Ventures, and Sofinnova Partners, playing pivotal roles in the financing.
- Healthcare – Actithera's work in radioligand therapies is positioned within the healthcare sector, specifically targeting advanced cancer treatments.
Financials
- 75.5 million – The total amount raised by Actithera in the Series A funding round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Actithera | Biotech Company | Company | A biotechnology company developing radiopharmaceuticals for cancer treatment. |
| M Ventures | Founding Investor | Company | The strategic corporate venture capital arm of Merck KGaA, it leads investments in biotech and technology sectors. |
| Hadean Ventures | Lead Investor | Company | A European life science fund manager supporting Actithera's Series A round. |
| Sofinnova Partners | Lead Investor | Company | A leading European venture capital firm in life sciences, participating in Actithera's funding. |
| 4BIO Capital | Lead Investor | Company | An international venture capital firm focused on advanced therapies. |
| Dr. Andreas Goutopoulos | Founder and CEO | Person | Founder and CEO of Actithera, expert in drug discovery with over 25 years of industry experience. |